Dataset Information


Potential strategies against resistance to CAR T-cell therapy in haematological malignancies.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy is a rapidly developing method for adoptive immunotherapy of tumours in recent years. CAR T-cell therapies have demonstrated unprecedented efficacy in the treatment of patients with haematological malignancies. A 90% complete response (CR) rate has been reported in patients with advanced relapse or refractory acute lymphoblastic leukaemia, while >50% CR rates have been reported in cases of chronic lymphocytic leukaemia and partial B-cell lymphoma. Despite the high CR rates, a subset of the patients with complete remission still relapse. The mechanism of development of resistance is not clearly understood. Some patients have been reported to demonstrate antigen-positive relapse, whereas others show antigen-negative relapses. Patients who relapse following CAR T-cell therapy, have very poor prognosis and novel approaches to overcome resistance are required urgently. Herein, we have reviewed current literature and research that have investigated the strategies to overcome resistance to CAR T-cell therapy.


PROVIDER: S-EPMC7576929 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7126394 | BioStudies
2020-01-01 | S-EPMC7487702 | BioStudies
2020-01-01 | S-EPMC7556410 | BioStudies
2019-01-01 | S-EPMC6973049 | BioStudies
2019-01-01 | S-EPMC6460418 | BioStudies
2020-01-01 | S-EPMC7564024 | BioStudies
1000-01-01 | S-EPMC5988064 | BioStudies
2020-01-01 | S-EPMC7216329 | BioStudies
2020-01-01 | S-EPMC7647970 | BioStudies
2019-01-01 | S-EPMC6904344 | BioStudies